75 related articles for article (PubMed ID: 17690700)
1. Nucleophosmin leukaemic mutants contain C-terminus peptides that bind HLA class I molecules.
Liso A; Colau D; Benmaamar R; De Groot A; Martin W; Benedetti R; Specchia G; Martelli MP; Coulie P; Falini B
Leukemia; 2008 Feb; 22(2):424-6. PubMed ID: 17690700
[No Abstract] [Full Text] [Related]
2. Altered HLA Class I Profile Associated with Type A/D Nucleophosmin Mutation Points to Possible Anti-Nucleophosmin Immune Response in Acute Myeloid Leukemia.
Kuželová K; Brodská B; Fuchs O; Dobrovolná M; Soukup P; Cetkovský P
PLoS One; 2015; 10(5):e0127637. PubMed ID: 25992555
[TBL] [Abstract][Full Text] [Related]
3. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.
Buzyn A; Ostankovitch M; Zerbib A; Kemula M; Connan F; Varet B; Guillet JG; Choppin J
Eur J Immunol; 1997 Aug; 27(8):2066-72. PubMed ID: 9295046
[TBL] [Abstract][Full Text] [Related]
4. Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules: studies in antigen-processing defective cell lines.
Cullis JO; Barrett AJ; Goldman JM; Lechler RI
Leukemia; 1994 Jan; 8(1):165-70. PubMed ID: 8289483
[TBL] [Abstract][Full Text] [Related]
5. Mapping of HLA class I binding motifs in forty-four fusion proteins involved in human cancers.
Gambacorti-Passerini C; Bertazzoli C; Dermime S; Scardino A; Schendel D; Parmiani G
Clin Cancer Res; 1997 May; 3(5):675-83. PubMed ID: 9815736
[TBL] [Abstract][Full Text] [Related]
6. Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin.
Kuželová K; Brodská B; Schetelig J; Röllig C; Ráčil Z; Walz JS; Helbig G; Fuchs O; Vraná M; Pecherková P; Šálek C; Mayer J
PLoS One; 2018; 13(12):e0204290. PubMed ID: 30557403
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin.
Narayan R; Olsson N; Wagar LE; Medeiros BC; Meyer E; Czerwinski D; Khodadoust MS; Zhang L; Schultz L; Davis MM; Elias JE; Levy R
PLoS One; 2019; 14(7):e0219547. PubMed ID: 31291378
[TBL] [Abstract][Full Text] [Related]
8. Identification and functional characterization of a cytoplasmic nucleophosmin leukaemic mutant generated by a novel exon-11 NPM1 mutation.
Albiero E; Madeo D; Bolli N; Giaretta I; Bona ED; Martelli MF; Nicoletti I; Rodeghiero F; Falini B
Leukemia; 2007 May; 21(5):1099-103. PubMed ID: 17301808
[No Abstract] [Full Text] [Related]
9. A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia.
Martelli MP; Manes N; Liso A; Pettirossi V; Verducci Galletti B; Bigerna B; Pucciarini A; De Marco MF; Pallotta MT; Bolli N; Sborgia M; di Raimondo F; Fabbiano F; Meloni G; Specchia G; Martelli MF; Falini B
Leukemia; 2008 Dec; 22(12):2285-8. PubMed ID: 18563173
[No Abstract] [Full Text] [Related]
10. In human genome, generation of a nuclear export signal through duplication appears unique to nucleophosmin (NPM1) mutations and is restricted to AML.
Liso A; Bogliolo A; Freschi V; Martelli MP; Pileri SA; Santodirocco M; Bolli N; Martelli MF; Falini B
Leukemia; 2008 Jun; 22(6):1285-9. PubMed ID: 18059485
[No Abstract] [Full Text] [Related]
11. Natural killer cell recognition of HLA class I molecules.
Brooks AG; Boyington JC; Sun PD
Rev Immunogenet; 2000; 2(3):433-48. PubMed ID: 11256749
[TBL] [Abstract][Full Text] [Related]
12. Specific recognition of HLA-E, but not classical, HLA class I molecules by soluble CD94/NKG2A and NK cells.
Brooks AG; Borrego F; Posch PE; Patamawenu A; Scorzelli CJ; Ulbrecht M; Weiss EH; Coligan JE
J Immunol; 1999 Jan; 162(1):305-13. PubMed ID: 9886400
[TBL] [Abstract][Full Text] [Related]
13. A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF.
Bolli N; De Marco MF; Martelli MP; Bigerna B; Pucciarini A; Rossi R; Mannucci R; Manes N; Pettirossi V; Pileri SA; Nicoletti I; Falini B
Leukemia; 2009 Mar; 23(3):501-9. PubMed ID: 19005479
[TBL] [Abstract][Full Text] [Related]
14. Anti-MUC1 antibodies react directly with MUC1 peptides presented by class I H2 and HLA molecules.
Apostolopoulos V; Chelvanayagam G; Xing PX; McKenzie IF
J Immunol; 1998 Jul; 161(2):767-75. PubMed ID: 9670953
[TBL] [Abstract][Full Text] [Related]
15. [Mutation of the nucleophosmin gene in acute myeloid leukemia].
Kiyoi H
Rinsho Ketsueki; 2006 Aug; 47(8):710-6. PubMed ID: 16986709
[No Abstract] [Full Text] [Related]
16. Distinctive expression of myelomonocytic markers and down-regulation of CD34 in acute myelogenous leukaemia with FLT3 tandem duplication and nucleophosmin mutation.
Mori Y; Yoshimoto G; Kumano T; Miyamoto T; Iino T; Takenaka K; Iwasaki H; Harada N; Kinukawa N; Nagafuji K; Teshima T; Shimoda K; Akashi K; Harada M
Eur J Haematol; 2007 Jul; 79(1):17-24. PubMed ID: 17598835
[TBL] [Abstract][Full Text] [Related]
17. Acute myeloid leukemia with mutated nucleophosmin (NPM1): molecular, pathological, and clinical features.
Falini B
Cancer Treat Res; 2010; 145():149-68. PubMed ID: 20306250
[TBL] [Abstract][Full Text] [Related]
18. Invariant chain association with MHC class I: preference for HLA class I/beta 2-microglobulin heterodimers, specificity, and influence of the MHC peptide-binding groove.
Vigna JL; Smith KD; Lutz CT
J Immunol; 1996 Nov; 157(10):4503-10. PubMed ID: 8906828
[TBL] [Abstract][Full Text] [Related]
19. Responses of peptide-specific T cells to stimulation with polystyrene beads carrying HLA class I molecules loaded with single peptides.
Chersi A; Galati R; Accapezzato D; Francavilla V; Barnaba V; Butler RH; Tanigaki N
J Immunol Methods; 2004 Aug; 291(1-2):79-91. PubMed ID: 15345307
[TBL] [Abstract][Full Text] [Related]
20. Class I-restricted alloreactive cytotoxic T lymphocytes recognize a complex array of specific MHC-associated peptides.
Wang W; Man S; Gulden PH; Hunt DF; Engelhard VH
J Immunol; 1998 Feb; 160(3):1091-7. PubMed ID: 9570521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
